Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Published:2014-11 Issue:11 Volume:121 Page:2181-2192
ISSN:0161-6420
Container-title:Ophthalmology
language:en
Short-container-title:Ophthalmology

Author:

Ho Allen C.,Busbee Brandon G.,Regillo Carl D.,Wieland Mark R.,Van Everen Sherri A.,Li Zhengrong,Rubio Roman G.,Lai Phillip

Publisher

Elsevier BV

Subject

Ophthalmology

Reference26 articles.

1. Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments;Rein;Arch Ophthalmol,2009

2. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis;Wong;Ophthalmology,2008

3. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes;Lopez;Invest Ophthalmol Vis Sci,1996

4. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006

5. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study;Brown;Ophthalmology,2009

Cited by 286 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials;Eye;2024-09-11

2. Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases;Eye;2024-08-31

3. High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab;Ophthalmology and Therapy;2024-08-30

4. TENAYA and LUCERNE;Ophthalmology;2024-08

5. Dosing vs Assessment Intervals With Faricimab and Aflibercept;JAMA Ophthalmology;2024-08-01